Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets
TORONTO and HAIFA, Israel, Sept. 14, 2026 — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces that its Israeli subsidiary, NurExone Biologic Ltd., has entered into a Memorandum of Understanding (the “MOU”) with NanoPass Technologies Ltd. (“NanoPass”), a medical device company specializing in precision delivery, to evaluate the integration of NanoPass’s MicronJet™ platform with NurExone’s exosome formulations for eye and skin applications.
NurExone’s exosomes are designed to act as biological delivery vehicles, targeting damaged tissue either on their own or carrying therapeutic cargo. NanoPass’s FDA-cleared MicronJet™ intradermal delivery platform provides precise, controlled and safe placement at the site of administration (leveraging advanced MEMS technology silicon-crystal pyramids).
Ophthalmology
NurExone is developing ExoPTEN for optic nerve damage, including glaucoma-related indications, following preclinical studies showing improvements in retinal function and retinal ganglion cell survival compared with controls.
The companies plan to evaluate NanoPass’s MicronJet™ technology for suprachoroidal delivery in a preclinical study comparing it with existing administration methods. The study will assess whether NanoPass’s platform can provide a practical, minimally invasive and consistent administration method that could support future clinical use, scale-up and commercialization. Precise delivery is important in the eye, and the suprachoroidal space offers a way to place treatment close to the retina and optic nerve while limiting exposure to other parts of the eye.
Dermatology and Aesthetics
The companies also plan to evaluate the use of MicronJet™ for intradermal delivery of NurExone’s exosome formulations for skincare and aesthetic applications.
A challenge in these applications is getting the exosomes beyond the skin’s natural barrier. Rather than remaining on the surface, NanoPass’s intradermal delivery technology is designed to place the formulation directly into the skin in a controlled and minimally invasive way.
For NurExone’s U.S. subsidiary, Exo-Top Inc., the collaboration could support development of an integrated exosome-and-delivery product that is straightforward for professional use and potentially easier to standardize and scale across applications such as skin rejuvenation and other aesthetic uses. The broader global regenerative aesthetics market is experiencing rapid expansion and is projected to grow from approximately US$17.7 billion in 2026 to approximately US$28.9 billion by 2030.1
Collaboration Terms
Under the MOU, the companies will evaluate NanoPass’s MicronJet™ platform with NurExone’s MSC-derived exosome formulations. Each party will fund its own activities; NurExone will own the preclinical proof-of-concept results, with newly developed IP jointly owned.
“Our exosome platform is designed to work across multiple indications, and NanoPass gives us an opportunity to test an additional administration approach where localized delivery may be especially useful,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “For eye and skin applications, we will evaluate whether the combination can create a practical, consistent and easy-to-use product format for future clinical and commercial use. ExoPTEN’s acute spinal cord injury program is advancing through a separate minimally invasive administration approach.”
“Exosomes are emerging as an important new class of biological products, and we believe they represent a significant new opportunity for our delivery platform,” said Daniel Levitats, Chief Executive Officer of NanoPass Technologies. “NurExone gives us the opportunity to evaluate MicronJet™ across both therapeutic and commercial exosome applications and potentially establish a new area of use for a technology already supported by extensive clinical experience.”
The MOU does not obligate either party to enter into a definitive commercial agreement and may be terminated by either party without cause on 30 days’ written notice. The full details of the collaboration agreement and the Company’s ongoing corporate and financial roadmaps can be accessed by visiting the Company’s website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.
About NanoPass Technologies Ltd.
NanoPass Technologies Ltd. is a global medical device company pioneering precision intradermal drug delivery. The company developed MicronJet™, the first FDA-cleared device specifically designed for true intradermal delivery (<1 mm), enabling accurate, consistent, and safe delivery into the dermis.
Supported by over 70 clinical studies and millions of successful treatments worldwide, NanoPass collaborates with pharmaceutical companies, researchers, and physicians all over the world to improve vaccine delivery, biologics administration, and regenerative aesthetic treatments.
About NurExone
NurExone is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the Company’s roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery for other indications. NurExone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.
Neither the TSX Venture Exchange nor its Regulation Services Provider, as that term is defined in the policies of the TSX Venture Exchange, accepts responsibility for the adequacy or accuracy of this release.
1. The Business Research Company, Regenerative Aesthetics Global Market Report 2026 (February 12, 2026), available through Global Information, Inc. at this link.
Ready to learn more about the rapidly expanding exosome market? View the “The Global Exosome Market – Market Size, Forecast, Trials and Trends, 2026.”
